Stay updated on Lebrikizumab in Atopic Dermatitis Clinical Trial

Sign up to get notified when there's something new on the Lebrikizumab in Atopic Dermatitis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lebrikizumab in Atopic Dermatitis Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    No substantive changes detected in the study details between the screenshots; only minor formatting or UI adjustments are visible. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-10-28T02:35:54.000Z thumbnail image
  3. Check
    31 days ago
    Change Detected
    Summary
    - Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.
    Difference
    1%
    Check dated 2025-10-06T15:51:22.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    Added a new page revision tag (v3.1.0) and removed several drug-safety topics, indicating a reorganization or narrowing of content rather than new substantive material.
    Difference
    0.1%
    Check dated 2025-09-29T09:48:15.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    Revision updated to v3.0.2 and Back to Top removed; overall a minor update with no substantive changes to core content, pricing, or availability.
    Difference
    0.1%
    Check dated 2025-09-14T23:48:33.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The page has been updated to include a new version of a publication regarding Lebrikizumab and its effects on inflammatory biomarkers, reflecting a more recent date and revision number.
    Difference
    0.2%
    Check dated 2025-09-07T20:26:59.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The web page has been updated to include new facility names and locations, particularly in South Korea and Poland, as well as a comprehensive list of publications related to the drug lebrikizumab. Additionally, drug safety information and details about skin conditions have been added.
    Difference
    17%
    Check dated 2025-08-31T12:41:17.000Z thumbnail image

Stay in the know with updates to Lebrikizumab in Atopic Dermatitis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lebrikizumab in Atopic Dermatitis Clinical Trial page.